2026-06-14T05:05:44Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/169322025-04-30T10:11:11Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608

00925njm 22002777a 4500 dc Thomadakis, Christos author Gountas, Ilias author Duffell, Erika author Gountas, Konstantinos author Bluemel, Benjamin author Seyler, Thomas author Pericoli, Filippo Maria author Kászoni-Rückerl, Irene author El-Khatib, Ziad author Busch, Martin author Schmutterer, Irene author Vanwolleghem, Thomas author Klamer, Sofieke author Plettinckx, Els author Mortgat, Laure author Van Beckhoven, Dominique author Varleva, Tonka author Kosanovic Licina, Mirjana Lana author Nemeth Blazic, Tatjana author Nonković, Diana author Theophanous, Fanitsa author Němeček, Vratislav author Maly, Marek author Christensen, Peer Brehm author Cowan, Susan author Rüütel, Kristi author Brummer-Korvenkontio, Henrikki author Brouard, Cécile author Steffen, Gyde author Krings, Amrei author Dudareva, Sandra author Zimmermann, Ruth author Nikolopoulou, Georgia author Molnár, Zsuzsanna author Kozma, Emese author Gottfredsson, Magnús author Murphy, Niamh author Kondili, Loreta A author Tosti, Maria Elena author Ciccaglione, Anna Rita author Suligoi, Barbara author Nikiforova, Raina author Putnina, Renate author Jancoriene, Ligita author Seguin-Devaux, Carole author Melillo, Tanya author Boyd, Anders author van der Valk, Marc author Op de Coul, Eline author Whittaker, Robert author Kløvstad, Hilde author Stępień, Małgorzata author Rosińska, Magdalena author Valente, Cristina author Marinho, Rui Tato author Popovici, Odette author Avdičová, Mária author Kerlik, Jana author Klavs, Irena author Maticic, Mojca author Diaz Franco, Asuncion author Amo, Julia del author Lundberg Ederth, Josefine author Axelsson, Maria author Nikolopoulos, Georgios author 2024-01 Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Lancet Reg Health Eur. 2024:36:100792. 10.1016/j.lanepe.2023.100792 2666-7762 The Lancet regional health. Europe 38188273 http://hdl.handle.net/20.500.12105/16932 HCV Hepatitis C Chronic hepatitis Prevalence Elimination Europe Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis